Abstract
Blood proteome analysis for biomarker discovery represents one of the most challenging tasks to be achieved through clinical proteomics due to the sample complexity, such as the extreme heterogeneity of proteins in very dynamic concentrations, and to the observation of proper sampling and storage conditions. Quantitative and qualitative proteomics profiling of plasma and serum could be useful both for the early detection of diseases and for the evaluation of pathological status. Two main sources of variability can affect the precision and accuracy of the quantitative experiments designed for biomarker discovery and validation. These sources are divided into two categories, pre-analytical and analytical, and are often ignored; however, they can contribute to consistent errors and misunderstanding in biomarker research. In this chapter, we review critical pre-analytical and analytical variables that can influence quantitative proteomics. According to guidelines accepted by proteomics community, we propose some recommendations and strategies for a proper proteomics analysis addressed to biomarker studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Geyer PE et al (2016) Plasma proteome profiling to assess human health and disease. Cell Syst 2(3):185–195
Pieragostino D et al (2010) Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J Proteome 73(3):579–592
Poulsen K et al (2012) Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods 56(2):284–292
Hubel A et al (2011) State of the art in preservation of fluid biospecimens. Biopreserv Biobank 9(3):237–244
Schoonenboom NS et al (2005) Effects of processing and storage conditions on amyloid β (1–42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51(1):189–195
Aldred S, Grant MM, Griffiths HR (2004) The use of proteomics for the assessment of clinical samples in research. Clin Biochem 37(11):943–952
Yi J, Craft D, Gelfand CA (2011) Minimizing preanalytical variation of plasma samples by proper blood collection and handling. Methods Mol Biol:137–149
Plebani M (2006) Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med 44(6):750–759
Del Boccio P et al (2007) Cleavage of cystatin C is not associated with multiple sclerosis. Ann Neurol 62(2):201–204
Greco V et al (2014) Direct analytical sample quality assessment for biomarker investigation: qualifying cerebrospinal fluid samples. Proteomics 14(17–18):1954–1962
Tuck MK et al (2008) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8(1):113–117
Rodak BF, Fritsma GA, Keohane E (2013) Hematology: clinical principles and applications. Elsevier Health Sciences, Amsterdam
Thomson JM (1984) Specimen collection for blood coagulation testing. Lab Hematol 2:833–863
Lista S, Faltraco F, Hampel H (2013) Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol 101-102:18–34
Ray S et al (2011) Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 11(11):2139–2161
Tammen H (2008) Specimen collection and handling: standardization of blood sample collection. Methods Mol Biol (Clifton, NJ) 428:35–42
Tammen H, Hess R (2011) Collection and handling of blood specimens for peptidomics. Methods Mol Biol (Clifton, NJ) 728:151–159
Luque-Garcia JL, Neubert TA (2007) Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J Chromatogr A 1153(1–2):259–276
Thadikkaran L et al (2005) Recent advances in blood-related proteomics. Proteomics 5(12):3019–3034
Adkins JN et al (2002) Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 1(12):947–955
Liotta LA, Ferrari M, Petricoin E (2003) Clinical proteomics: written in blood. Nature 425(6961):905
Diamandis EP (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool – opportunities and potential limitations. Mol Cell Proteomics 3(4):367–378
Diamandis EP (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96(5):353–356
Tammen H et al (2005) Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5(13):3414–3422
Greening DW, Simpson RJ (2011) Low-molecular weight plasma proteome analysis using centrifugal ultrafiltration. Methods Mol Biol 728:109–124
Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845–867
Hu S, Loo JA, Wong DT (2006) Human body fluid proteome analysis. Proteomics 6(23):6326–6353
Hortin GL, Sviridov D (2010) The dynamic range problem in the analysis of the plasma proteome. J Proteome 73(3):629–636
Cetın N et al (2016) Serum albumin and von Willebrand factor: possible markers for early detection of vascular damage in children undergoing peritoneal dialysis. Clin Investig Med 39(4):E111
Can B et al (2016) Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res:1–8
ABBRITTI RV et al (2016) Meningiomas and proteomics: focus on new potential biomarkers and molecular pathways. Cancer Genomics Proteomics 13(5):369–379
LeVine SM (2016) Albumin and multiple sclerosis. BMC Neurol 16(1):1
Greifenhagen U et al (2016) Plasma proteins modified by advanced Glycation end products (AGEs) reveal site-specific susceptibilities to glycemic control in patients with type 2 diabetes. J Biol Chem 291(18):9610–9616
Chung L et al (2014) Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res 16(3):R63
Suman S et al (2016) Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer. J Proteome 148:183–193
Li D, Chan DW (2014) Proteomic cancer biomarkers from discovery to approval: it’s worth the effort. Expert Rev Proteomics 11(2):135–136
Crutchfield CA et al (2016) Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics 13(1):1
Percy AJ et al (2016) Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential. Expert Rev Proteomics 13(7):673–684
Pant P et al (2016) Serum sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of patients with membranous nephropathy and focal and segmental glomerulosclerosis. Saudi J Kidney Dis Transpl 27(3):539
Sun Y et al (2016) Identification of apolipoprotein CI peptides as a potential biomarker and its biological roles in breast cancer. Med Sci Monitor 22:1152
Streng AS et al (2016) Development of a targeted selected ion monitoring assay for the elucidation of protease induced structural changes in cardiac troponin T. J Proteome 136:123–132
Zhao W et al (2015) Screening and identification of apolipoprotein AI as a potential hepatoblastoma biomarker in children, excluding inflammatory factors. Oncol Lett 10(1):233–239
Janvilisri T et al (2015) Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach. Dis Markers 2015
Mondal G et al (2016) Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J 33(2):209–218
Piras C et al (2014) Serum protein profiling of early and advanced stage Crohn’s disease. EuPA Open Proteom 3:48–59
Christensen B et al (2015) Serum proteomic changes after randomized prolonged erythropoietin treatment and/or endurance training: detection of novel biomarkers. PLoS One 10(2):e0117119
de Seny D et al (2016) Biomarkers of inflammation and innate immunity in atrophic nonunion fracture. J Transl Med 14(1):258
Heywood WE et al (2016) Global serum glycoform profiling for the investigation of dystroglycanopathies & congenital disorders of glycosylation. Mol Genet Metab Rep 7:55–62
Wu F et al (2015) Identification of phosphorylated MYL12B as a potential plasma biomarker for septic acute kidney injury using a quantitative proteomic approach. Int J Clin Exp Pathol 8(11):14409
Okano T et al (2016) Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling. Int J Oncol 48(3):945–952
Viennois E et al (2015) Longitudinal study of circulating protein biomarkers in inflammatory bowel disease. J Proteome 112:166–179
Nguyen VA et al (2016) A pathway proteomic profile of ischemic stroke survivors reveals innate immune dysfunction in association with mild symptoms of depression-a pilot study. Front Neurol 7:85
Ruland T et al (2016) Molecular serum signature of treatment resistant depression. Psychopharmacology 233(15–16):3051–3059
Lin Q et al (2015) Analysis of colorectal cancer glyco-secretome identifies laminin β-1 (LAMB1) as a potential serological biomarker for colorectal cancer. Proteomics 15(22):3905–3920
Gu H et al (2016) Quantitative profiling of post-translational modifications by immunoaffinity enrichment and LC-MS/MS in cancer serum without immunodepletion. Mol Cell Proteomics 15(2):692–702
Boichenko AP et al (2014) A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer. J Proteome Res 13(11):4995–5007
Tonry CL et al (2015) Discovery and longitudinal evaluation of candidate protein biomarkers for disease recurrence in prostate cancer. J Proteome Res 14(7):2769–2783
McArdle A et al (2015) Developing clinically relevant biomarkers in inflammatory arthritis: a multiplatform approach for serum candidate protein discovery. Proteomics Clin Appl 10(6):691–698
Lin C et al (2016) ITRAQ-based quantitative proteomics reveals apolipoprotein AI and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Medicine 95(31):e4527
Wang X et al (2016) iTRAQ-based proteomics screen identifies LIPOCALIN-2 (LCN-2) as a potential biomarker for colonic lateral-spreading tumors. Sci Rep 6
Wang Q et al (2016) iTRAQ technology-based identification of human peripheral serum proteins associated with depression. Neuroscience 330:291–325
Lee SE et al (2015) Plasma proteome biomarkers of inflammation in school aged children in Nepal. PLoS One 10(12):e0144279
Xiao H et al (2016) Differential proteomic analysis of human saliva using tandem mass tags quantification for gastric cancer detection. Sci Rep 6
Cominetti O et al (2015) Proteomic biomarker discovery in 1000 human plasma samples with mass spectrometry. J Proteome Res 15(2):389–399
Rosenling T et al (2009) The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteome Res 8(12):5511–5522
Takehana S et al The effects of pre-analysis sample handling on human plasma amino acid concentrations. Clin Chim Acta 2016;455:68–74.
Mirjanic-Azaric B et al (2015) The impact of time of sample collection on the measurement of thyroid stimulating hormone values in the serum. Clin Biochem 48(18):1347–1349
Banks RE et al (2005) Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51(9):1637–1649
Caisey JD, King DJ (1980) Clinical chemical values for some common laboratory animals. Clin Chem 26(13):1877–1879
Percy AJ, Parker CE, Borchers CH (2013) Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies. Bioanalysis 5(22):2837–2856
Lundblad RL (2005) Considerations for the use of blood plasma and serum for proteomic analysis. Int J Gastroenterol 1:1–11
Omenn GS (2004) The human proteome organization plasma proteome project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 4(5):1235–1240
Omenn GS (2007) THE HUPO human plasma proteome project. Proteomics Clin Appl 1(8):769–779
Omenn GS et al (2005) Overview of the HUPO plasma proteome project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5(13):3226–3245
Lippi G et al (2006) Influence of hemolysis on routine clinical chemistry testing. Clin Chem Lab Med 44(3):311–316
Lippi G et al (2005) Preanalytical variability in laboratory testing: influence of the blood drawing technique. Clin Chem Lab Med 43(3):319–325
Rodriguez AD, Gonzalez PA (2009) Diurnal variations in biomarkers used in cardiovascular medicine: clinical significance. Rev Esp Cardiol 62(11):1340–1341
Capila I, Linhardt RJ (2002) Heparin-protein interactions. Angew Chem Int Ed Engl 41(3):391–412
Dammann CE et al (2006) Protein detection in dried blood by surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF MS). Biol Neonate 89(2):126–132
Rai AJ et al (2005) HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5(13):3262–3277
Ahn S-M, Simpson RJ (2007) Proteomic strategies for analyzing body fluids. In: Thongboonkerd V (ed) Proteomics of human body fluids. Springer, New York, NY, pp 3–30
Jambunathan K, Galande AK (2014) Sample collection in clinical proteomics—Proteolytic activity profile of serum and plasma. Proteomics Clin Appl 8(5–6):299–307
White JG (2000) EDTA-induced changes in platelet structure and function: clot retraction. Platelets 11(1):49–55
Drake SK et al (2004) Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clin Chem 50(12):2398–2401
Hsieh SY et al (2006) Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 6(10):3189–3198
Villanueva J et al (2005) Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4(4):1060–1072
Zimmerman LJ et al (2012) Global stability of plasma proteomes for mass spectrometry-based analyses. Mol Cell Proteomics 11(6):M111.014340
Mateos J et al (2017) Multicentric study of the effect of pre-analytical variables in the quality of plasma samples stored in biobanks using different complementary proteomic methods. J Proteome 150:109–120
Martino TA et al (2007) Diurnal protein expression in blood revealed by high throughput mass spectrometry proteomics and implications for translational medicine and body time of day. Am J Phys Regul Integr Comp Phys 293(3):R1430–R1437
Robles MS, Mann M (2013) Proteomic approaches in circadian biology, in Circadian clocks. Springer, New York, NY, pp 389–407
Apweiler R et al (2009) Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med 47(6):724–744
Rosenling T et al (2011) The impact of delayed storage on the measured proteome and Metabolome of human cerebrospinal fluid. Clin Chem 57(12):1703–1711
Pieragostino D et al (2013) Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. Proteomics 13(6):1002–1009
Marshall J et al (2003) Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2(4):361–372
West-Nielsen M et al (2005) Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem 77(16):5114–5123
Rai AJ, Vitzthum F (2006) Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 3(4):409–426
Whiteaker JR et al (2010) An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 9(1):184–196
Whiteaker JR et al (2011) Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics 10(4):110.005645
Ahmed N et al (2003) An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 3(10):1980–1987
Björhall K, Miliotis T, Davidsson P (2005) Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 5(1):307–317
Steel LF et al (2003) Efficient and specific removal of albumin from human serum samples. Mol Cell Proteomics 2(4):262–270
Gong Y et al (2006) Different immunoaffinity fractionation strategies to characterize the human plasma proteome. J Proteome Res 5(6):1379–1387
Fu Q et al (2005) A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis. Proteomics 5(10):2656–2664
Barquinero NC (2016) Identification and quantitation of proteins in human plasma and serum by LC-MS/MS. Nat Methods PMCID:PMC3943160
Horn A et al (2006) Multidimensional proteomics of human serum using parallel chromatography of native constituents and microplate technology. Proteomics 6(2):559–570
Tang HY et al (2005) A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 5(13):3329–3342
Olsen JV, Ong S-E, Mann M (2004) Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol Cell Proteomics 3(6):608–614
Olsen, J.V., S.-E. Ong, and M. Mann, Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Molecular & Cellular Proteomics, 2004. 3(6): p. 608-614.
Proc JL et al (2010) A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J Proteome Res 9(10):5422–5437
Zhou J et al (2006) Evaluation of the application of sodium deoxycholate to proteomic analysis of rat hippocampal plasma membrane. J Proteome Res 5(10):2547–2553
Burkhart JM et al (2012) Systematic and quantitative comparison of digest efficiency and specificity reveals the impact of trypsin quality on MS-based proteomics. J Proteome 75(4):1454–1462
Hoofnagle AN, Wener MH (2009) The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 347(1):3–11
Percy AJ et al (2013) Absolute quantitation of proteins in human blood by multiplexed multiple reaction monitoring mass spectrometry. Methods Mol Biol:167–189
Keshishian H et al (2007) Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 6(12):2212–2229
Lehmann S et al (2013) Quantitative clinical chemistry proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin Chem Lab Med 51(5):919–935
Hoofnagle AN (2010) Quantitative clinical proteomics by liquid chromatography–tandem mass spectrometry: assessing the platform. Clin Chem 56(2):161–164
Karsan A et al (2005) Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 51(8):1525–1528
Bae YJ et al (2012) Degree of ionization in MALDI of peptides: thermal explanation for the gas-phase ion formation. J Am Soc Mass Spectrom 23(8):1326–1335
Westmacott G et al (2002) The influence of laser fluence on ion yield in matrix-assisted laser desorption ionization mass spectrometry. Int J Mass Spectrom 221(1):67–81
Frey BL et al (2005) Controlling gas-phase reactions for efficient charge reduction electrospray mass spectrometry of intact proteins. J Am Soc Mass Spectrom 16(11):1876–1887
Bae YJ, Park KM, Kim MS (2012) Reproducibility of temperature-selected mass spectra in matrix-assisted laser desorption ionization of peptides. Anal Chem 84(16):7107–7111
O'Rourke MB, Djordjevic SP, Padula MP (2016) The quest for improved reproducibility in MALDI mass spectrometry. Mass Spectr Rev. doi:10.1002/mas.21515
Gallien S, Domon B (2015) Detection and quantification of proteins in clinical samples using high resolution mass spectrometry. Methods 81:15–23
Gallien, S. and B. Domon, Detection and quantification of proteins in clinical samples using high resolution mass spectrometry. Methods, 2015. 81: p. 15-23.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Greco, V., Piras, C., Pieroni, L., Urbani, A. (2017). Direct Assessment of Plasma/Serum Sample Quality for Proteomics Biomarker Investigation. In: Greening, D., Simpson, R. (eds) Serum/Plasma Proteomics. Methods in Molecular Biology, vol 1619. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7057-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7057-5_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7056-8
Online ISBN: 978-1-4939-7057-5
eBook Packages: Springer Protocols